118.94
3.38 (2.92%)
| Previous Close | 115.56 |
| Open | 116.10 |
| Volume | 1,769,715 |
| Avg. Volume (3M) | 2,059,290 |
| Market Cap | 18,185,926,656 |
| Price / Earnings (TTM) | 21.82 |
| Price / Earnings (Forward) | 24.21 |
| Price / Sales | 4.46 |
| Price / Book | 6.98 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -22.27% |
| Operating Margin (TTM) | 17.67% |
| Diluted EPS (TTM) | -6.08 |
| Quarterly Revenue Growth (YOY) | -3.30% |
| Total Debt/Equity (MRQ) | 110.09% |
| Current Ratio (MRQ) | 1.86 |
| Operating Cash Flow (TTM) | 1.00 B |
| Levered Free Cash Flow (TTM) | 381.00 M |
| Return on Assets (TTM) | 4.96% |
| Return on Equity (TTM) | -23.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Illumina, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.60 |
|
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.19% |
| % Held by Institutions | 101.16% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Corvex Management Lp | 31 Dec 2025 | 3,829,608 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 170.00 (Piper Sandler, 42.93%) | Buy |
| 170.00 (Guggenheim, 42.93%) | Buy | |
| Median | 152.50 (28.22%) | |
| Low | 120.00 (JP Morgan, 0.89%) | Hold |
| Average | 150.83 (26.81%) | |
| Total | 3 Buy, 3 Hold | |
| Avg. Price @ Call | 140.05 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 09 Feb 2026 | 170.00 (42.93%) | Buy | 117.25 |
| JP Morgan | 06 Feb 2026 | 120.00 (0.89%) | Hold | 119.72 |
| Canaccord Genuity | 26 Jan 2026 | 150.00 (26.11%) | Hold | 153.00 |
| 22 Dec 2025 | 130.00 (9.30%) | Hold | 137.60 | |
| Guggenheim | 26 Jan 2026 | 170.00 (42.93%) | Buy | 153.00 |
| 05 Jan 2026 | 144.00 (21.07%) | Buy | 141.33 | |
| Stifel | 20 Jan 2026 | 155.00 (30.32%) | Buy | 147.17 |
| TD Cowen | 07 Jan 2026 | 140.00 (17.71%) | Hold | 150.14 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |